Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial

被引：1
|
作者：
Aranda, E. [1 ]
Ia-Alfonso, P. Garc ' [2 ]
Benavides, M. [3 ]
Sanchez-Ruiz, A. [4 ]
Guillen-Ponce, C. [5 ]
Safont, M. J. [6 ]
Alcaide, J. [7 ]
Gomez, A. [1 ]
Lopez, R. [8 ]
Manzano, J. L. [9 ]
Mendez-Urena, M. [10 ]
Lopez, C. [11 ]
Garcia-Paredes, B. [12 ,13 ]
Gravalos, C. [14 ]
Garcia-Garcia, T. [15 ]
Falco, E. [16 ]
Martin-Valades, J. I. [17 ]
Gonzalez-Flores, E. [18 ]
Navalon, M. [19 ]
Diaz-Rubio, E. [12 ,13 ]
机构：
[1] Univ Cordoba, Maimonides Inst Biomed Res IMIBIC, Reina Sofia Hosp,Med Oncol, Spanish Canc Network RTICC,Inst Salud Carlos III, Cordoba, Spain
[2] Gregorio Maranon Hosp, Med Oncol, Madrid, Spain
[3] Hosp Univ Reg & Virgen de la Victoria, Med Oncol, Malaga, Spain
[4] Puerta de Hierro Hosp, Med Oncol, Madrid, Spain
[5] Univ Ramon & Cajal Hosp, Med Oncol, Madrid, Spain
[6] Univ Gen Hosp, Med Oncol, Valencia, Spain
[7] Costa del Sol Hosp, Med Oncol, Malaga, Spain
[8] Hosp Clin Santiago, Med Oncol, Santiago De Compostela, Spain
[9] Germans Trias & Pujol Hosp ICO, Med Oncol, Badalona, Spain
[10] Hosp Mostoles, Med Oncol, Mostoles, Spain
[11] Marques de Valdecilla Hosp, Med Oncol, Santander, Spain
[12] HC San Carlos, Madrid, Spain
[13] Inst Carlos III, Spanish Minist Sci & Innovat, Med Madrid, Ctr Affiliated Red Temat Invest Cooperat RD06 002, Madrid, Spain
[14] Doce Octubre Hosp, Med Oncol, Madrid, Spain
[15] Morales Meseguer Hosp, Med Oncol, Murcia, Spain
[16] Son Llatzer Hosp, Med Oncol, Palma De Mallorca, Spain
[17] Fdn Jimenez Diaz, Med Oncol, E-28040 Madrid, Spain
[18] Virgen de las Nieves Hosp, Med Oncol, Granada, Spain
[19] Complejo Asistencial, Med Oncol, Zamora, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31044-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2122
引用
收藏
页码：S371 / S372
页数：2
相关论文
共 50 条
  • [31] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - an interim analysis of the CEBIFOX trial
    Hoehler, T.
    Decker, T.
    Schimanski, C.
    Schmitz, S.
    Kanzler, S.
    Rauh, J.
    Vehling-Kaiser, U.
    Bernhard, H.
    Hoffmann, T.
    Niederle, N.
    von Verschuer, U.
    von Wichert, G.
    Wagner, T.
    Klein, M.
    ONKOLOGIE, 2013, 36 : 105 - 105
  • [32] A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
    Uetake, Hiroyuki
    Emi, Yasunori
    Yamanaka, Takeharu
    Muro, Kei
    Oki, Eiji
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [33] Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer A Randomized Phase 2 Clinical Trial
    Cremolini, Chiara
    Antoniotti, Carlotta
    Lonardi, Sara
    Aprile, Giuseppe
    Bergamo, Francesca
    Masi, Gianluca
    Grande, Roberta
    Tonini, Giuseppe
    Mescoli, Claudia
    Cardellino, Giovanni Gerardo
    Coltelli, Luigi
    Salvatore, Lisa
    Corsi, Domenico Cristiano
    Lupi, Cristiana
    Gemma, Donatello
    Ronzoni, Monica
    Dell'Aquila, Emanuela
    Marmorino, Federica
    Di Fabio, Francesca
    Mancini, Maria Laura
    Marcucci, Lorenzo
    Fontanini, Gabriella
    Zagonel, Vittorina
    Boni, Luca
    Falcone, Alfredo
    JAMA ONCOLOGY, 2018, 4 (04) : 529 - 536
  • [34] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [35] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hohler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Reis, Henning
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kostbade, Karina
    Virchow, Isabel
    Ting, Saskia
    Worm, Karl
    Schmid, Kurt W.
    Herold, Thomas
    Wiesweg, Marcel
    Schuler, Martin
    Trarbach, Tanja
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 236 - +
  • [36] Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group
    Heinemann, V.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H. G.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer
    Price, Timothy
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wenfeng
    Gibbs, Peter
    Lim, Robert
    Cheng, Ann-Lii
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (04) : 225 - 230
  • [38] Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
    F Kullmann
    S Hollerbach
    M M Dollinger
    J Harder
    M Fuchs
    H Messmann
    J Trojan
    E Gäbele
    A Hinke
    C Hollerbach
    E Endlicher
    British Journal of Cancer, 2009, 100 : 1032 - 1036
  • [39] Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
    Kullmann, F.
    Hollerbach, S.
    Dollinger, M. M.
    Harder, J.
    Fuchs, M.
    Messmann, H.
    Trojan, J.
    Gaebele, E.
    Hinke, A.
    Hollerbach, C.
    Endlicher, E.
    BRITISH JOURNAL OF CANCER, 2009, 100 (07) : 1032 - 1036
  • [40] CETUXIMAB PLUS XELIRI VERSUS CETUXIMAB PLUS XELOX AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): ANALYSIS OF THE RANDOMIZED TRIAL OF THE GERMAN AIO CRC STUDY GROUP: KRK-0204
    Stintzing, S.
    Jung, A.
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H.
    von Weikersthal, L. Fischer
    Moosmann, N.
    Kirchner, T.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 189 - 190
12345